Detected ·
Thryv Therapeutics Inc.
$30MSeries B
Montreal-based Thryv Therapeutics Inc. announced a $30M Series B financing led by InClin, Inc., with continued support from existing investors, to fund the ASPIRE-HF Phase 2a study of THRV-1268 in heart failure.
- Website
- thryvtrx.com
- linkedin.com/company/55183389
- Amount
- $30 000 000 USD
- Stage
- Series B
- Event
- Funding round
- Detected
- 2026-11-05 16:06:50 UTC
- Signal ID
- b1c3b9ac-fab8-4ed6-8b26-fc6af7f05e3d
As the API returns it
{
"id": "b1c3b9ac-fab8-4ed6-8b26-fc6af7f05e3d",
"created_at": "2026-11-05T16:06:50.577640Z",
"company_name": "Thryv Therapeutics Inc.",
"company_website_url": "thryvtrx.com",
"company_linkedin_url": "https://www.linkedin.com/company/55183389",
"event_type": "funding",
"funding_amount": 30000000,
"funding_currency": "USD",
"funding_stage": "series_b",
"message": "*Montreal-based Thryv Therapeutics Inc. announced a $30M Series B financing led by InClin, Inc., with continued support from existing investors, to fund the ASPIRE-HF Phase 2a study of THRV-1268 in heart failure.*"
}